Indian Biotechnology Sector

India’s bioeconomy has seen remarkable expansion, growing from US$ 10 billion in 2014 to US$ 140 billion by 2024, and is projected to reach US$ 300 billion by 2030. The vaccine industry alone is expected to grow from US$ 2 billion to US$ 5 billion as both domestic and global pharmaceutical companies increasingly include vaccines in their portfolios. India’s biotechnology market size was valued at approximately US$ 37.1 billion in 2025 with an expected compound annual growth rate (CAGR) of 13.09% during 2026-34, potentially reaching US$ 112.2 billion by 2034. Growth drivers include rising demand for personalized medicine, chronic disease treatments, and integration of IT with biotech for precision medicine. India’s cell and gene therapy market is projected to reach US$ 1.65 billion by 2027, growing robustly. Bharat Biotech, $SYNGENE , $LAURUSLABS , and Aragen are entering next-gen medicine manufacturing, including approvals for two indigenous CAR-T therapies, expected to make advanced cancer and genetic treatments more accessible and affordable. India’s cost-effective research environment, strong biotech talent pool, and public-private partnerships as key drivers for the country’s emergence as a trusted global leader in affordable precision healthcare and biotech innovation.